Camrelizumab combined with GP regimen concurrent chemoradiotherapy in treatment of nasopharyngeal carcinoma:a clinical study
Objective To determine the clinical efficacy of Camrelizumab combined with Gemcitabine+Cisplatin(GP)regimen in the treatment of nasopharyngeal carcinoma(NPC),and to analyze the effect of combined treatment on the survival of NPC patients.Methods A total of 120 NPC patients admitted to Xi'an North Hospital between March 2018 and March 2020 were included as the subjects in the study.According to the treatment methods,all patients were divided into the study group and control group(n=60 each).The control group was treated with GP regimen concurrent chemoradiotherapy,and the study group was treated with Camrelizumab com-bined with GP regimen concurrent chemoradiotherapy.After 4 cycles of treatment,the tumor remission in the two groups was compared.All patients were followed up for 2 years after 4 cycles of treatment.The overall survival,distant metastasis free survival and local recurrence free survival were recorded.The occurrence of toxic and ad-verse reactions during the treatment was recorded.Results After 4 cycles of treatment,the total effective rate in the study group was higher than that in the control group,with statistically significant difference(P＜0.05).During the 2-year follow-up,there were 3 cases(5％)of death,6 cases(10％)of distant metastasis and 9 cases(15％)of local recurrence in the study group,and there were 10 cases(17％)of death,12 cases(20％)of distant recurrence and 17 cases(28％)of local recurrence in the control group.The overall survival and local recurrence free survival in the study group were higher than those in the control group,with statistically significant differences(both P＜0.05).There was no statistical significant difference in toxic and adverse reactions between the two groups(P＞0.05).Conclusion Camrelizumab combined with GP regimen concurrent chemoradiotherapy may effectively im-prove the clinical effect in NPC patients,prolong the survival,and will not significantly increase the risk of toxic and adverse reactions.
万方数据
维普
